Dave Greenwald (Deerfield)

Deer­field-backed biotech emerges from stealth with gene ther­a­py de­liv­ery plat­forms from Har­vard and MIT

As a PhD stu­dent at Tufts, Dave Green­wald stud­ied the use of ade­no-as­so­ci­at­ed virus (AAV) vec­tors to de­liv­er gene ther­a­pies to peo­ple with re­tini­tis pig­men­tosa, a group of rare ge­net­ic eye dis­eases that caus­es the reti­na to break down over time.

While he lat­er left lab life, he now sits at the helm of Aper­tu­ra Gene Ther­a­py, a biotech that hopes to cus­tomize AAV vec­tors that are used wide­ly in de­liv­er­ing most gene ther­a­pies. Aper­tu­ra an­nounced its launch from stealth with $67 mil­lion in Se­ries A fi­nanc­ing from Deer­field, where Green­wald is al­so a vice pres­i­dent of busi­ness de­vel­op­ment.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.